Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

12.85 +0.07 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,951
Open 12.84
Bid (Size) 5.160 (2)
Ask (Size) 13.25 (5)
Prev. Close 12.78
Today's Range 12.80 - 12.95
52wk Range 5.200 - 14.04
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via Globe NewsWire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via Globe NewsWire

Performance

YTD
+28.37%
+28.37%
1 Month
+7.53%
+7.53%
3 Month
+110.31%
+110.31%
6 Month
+71.33%
+71.33%
1 Year
+14.83%
+14.83%

More News

Read More
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via Globe NewsWire
Why Shares of Alvotech Jumped This Week
Via The Motley Fool
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via Globe NewsWire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via Globe NewsWire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via Globe NewsWire
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via Globe NewsWire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via Globe NewsWire
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via Globe NewsWire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via Globe NewsWire
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via Globe NewsWire
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via Globe NewsWire
Alvotech Secures Financing Facilities of Approximately $136 Million
From Alvotech
Via Globe NewsWire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
From Alvotech
Via Globe NewsWire
Earnings Scheduled For November 15, 2022
Via Benzinga
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
From Alvotech
Via Globe NewsWire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
From Alvotech
Via Globe NewsWire
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
From Alvotech
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.